UC, MIT Battle Over Patent to Gene-Editing Tool
By Lisa M. Krieger,
San Jose Mercury News
| 05. 09. 2015
Will the University of California reap the financial rewards of CRISPR's commercial use, likely worth billions of dollars? That's the source of a bitter fight.
In June 2012, UC Berkeley's Jennifer Doudna and Emmanuelle Charpentier, now a professor in Germany, showed how bacteria's natural defense system could be turned into a "gene editing" tool to cut DNA strands.
Seven months later, Feng Zhang of the Massachsuetts Institute of Technology, along with Harvard's George Church, showed that the tool also works in human cells.
UC and Doudna filed for a patent first. But in a shocking turn of events, MIT and Zhang won last month, earning the patent that covers use of CRISPR in every species except bacteria, including humans.
MIT paid extra to expedite Zhang's patent application. MIT and Zhang also assert that the patent belongs to them because Doudna didn't prove it works in human cells, only bacterial cells.
Zhang also submitted photos of lab notebooks showing his lab work was ahead of Doudna's.
UC and Doudna are fighting back, submitting thousands of pages of documentation to support their...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Lucy Tu, The Guardian | 11.05.2025
Beth Schafer lay in a hospital bed, bracing for the birth of her son. The first contractions rippled through her body before she felt remotely ready. She knew, with a mother’s pit-of-the-stomach intuition, that her baby was not ready either...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...